CNMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Conmed Corp (CNMD) is not a strong buy at the moment for a beginner investor with a long-term focus. The stock is facing challenges such as declining revenue projections, reduced earnings, and lack of significant positive catalysts. While the company's revenue has grown modestly in the latest quarter, its net income and EPS have dropped significantly. Additionally, there are no strong trading signals or influential figures backing the stock recently. Given the investor's profile and the current data, holding off on purchasing CNMD is the most prudent decision.
The MACD is negative and expanding, indicating bearish momentum. RSI is at 20.153, suggesting the stock is oversold but not providing a clear buy signal. Moving averages are converging, showing no strong trend. The stock is trading below key support levels, with S1 at 42.143 and S2 at 40.765, indicating potential further downside.
The exit from gastroenterology product lines is expected to improve gross margins, though this will not be realized until 2026.
Revenue growth has slowed significantly, with projections of a 1.3% decline over the next 12 months.
Net income and EPS have dropped sharply in the latest quarter.
Analysts have lowered price targets, and the stock lacks significant trading or insider activity.
The company's small scale in the healthcare sector limits its competitive edge.
In Q4 2025, revenue increased by 7.88% YoY to $373.2M. However, net income dropped by 50.41% YoY to $16.7M, and EPS fell by 50% YoY to 0.54. Gross margin improved slightly by 2.02% YoY to 58.49%.
BofA has lowered the price target from $65 to $52, maintaining a Neutral rating. The exit from gastroenterology product lines is seen as accretive to gross margins but dilutive to earnings in 2026.
